Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272–87. https://doi.org/10.1093/cvr/cvac013.

Article  CAS  PubMed  Google Scholar 

Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–1032. https://doi.org/10.1161/CIR.0000000000001063.

Article  PubMed  Google Scholar 

Wright EM, Loo DDF, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733–94. https://doi.org/10.1152/physrev.00055.2009.

Article  CAS  PubMed  Google Scholar 

Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(4):422–34. https://doi.org/10.1016/j.jacc.2019.11.031.

Article  CAS  PubMed  Google Scholar 

Inzucchi SE, Kosiborod M, Fitchett D, et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation. 2018;138(17):1904–7. https://doi.org/10.1161/circulationaha.118.035759.

Article  PubMed  Google Scholar 

McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. New Engl J Med. 2019;381(21):1995–2008. https://doi.org/10.1056/NEJMoa1911303.

Article  CAS  PubMed  Google Scholar 

Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. Ne Engl J Med. 2020;383(15):1413–24. https://doi.org/10.1056/NEJMoa2022190.

Article  CAS  Google Scholar 

Lip GY, Heinzel FR, Gaita F, et al. European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace. 2016;18(1):12–36. https://doi.org/10.1093/europace/euv191.

Article  PubMed  Google Scholar 

Podrid PJ, Fogel RI, Fuchs TT. Ventricular arrhythmia in congestive heart failure. American journal of cardiology. 1992;69(18):82G-95G; discussion 95G-96G. https://doi.org/10.1016/0002-9149(92)91257-5.

Article  CAS  PubMed  Google Scholar 

Watanabe E, Tanabe T, Osaka M, et al. Sudden cardiac arrest recorded during Holter monitoring: prevalence, antecedent electrical events, and outcomes. Heart Rhythm. 2014;11(8):1418–25. https://doi.org/10.1016/j.hrthm.2014.04.036.

Article  PubMed  Google Scholar 

Fernandes GC, Fernandes A, Cardoso R, et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials. Heart Rhythm. 2021;18(7):1098–105. https://doi.org/10.1016/j.hrthm.2021.03.028.

Article  PubMed  Google Scholar 

Sfairopoulos D, Zhang N, Wang Y, et al. Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials. Europace. 2022;24(1):20–30. https://doi.org/10.1093/europace/euab177.

Article  PubMed  Google Scholar 

Yin Z, Zheng H, Guo Z. Effect of sodium-glucose co-transporter protein 2 inhibitors on arrhythmia in heart failure patients with or without type 2 diabetes: a meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2022;9: 902923. https://doi.org/10.3389/fcvm.2022.902923.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scheen AJ. Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: a comprehensive review ranging from sulphonylureas to SGLT2 inhibitors. Diabetes Metab. 2022;48(6): 101405. https://doi.org/10.1016/j.diabet.2022.101405.

Article  CAS  PubMed  Google Scholar 

Fawzy AM, Rivera-Caravaca JM, Underhill P, Fauchier L, Lip GYH. Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: insights from a global federated electronic medical record database. Diabetes Obes Metab. 2023;25(2):602–10. https://doi.org/10.1111/dom.14854.

Article  CAS  PubMed  Google Scholar 

Curtain JP, Docherty KF, Jhund PS, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Euro Heart J. 2021;42(36):3727–38. https://doi.org/10.1093/eurheartj/ehab560.

Article  CAS  Google Scholar 

Fujiki S, Iijima K, Nakagawa Y, et al. Effect of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes treated with an implantable cardioverter-defibrillator: the EMPA-ICD trial. Cardiovasc Diabetol. 2024;23(1):224. https://doi.org/10.1186/s12933-024-02309-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benedikt M, Oulhaj A, Rohrer U, et al. Ertugliflozin to reduce arrhythmic burden in patients with ICDs/CRT-Ds. NEJM evidence. 2024;3(10):EVIDoa2400147. https://doi.org/10.1056/EVIDoa2400147.

Article  PubMed  Google Scholar 

McMurray JJV, Docherty KF, de Boer RA, et al. Effect of dapagliflozin versus placebo on symptoms and 6-minute walk distance in patients with heart failure: the DETERMINE randomized clinical trials. Circulation. 2024;149(11):825–38. https://doi.org/10.1161/circulationaha.123.065061.

Article  CAS  PubMed  Google Scholar 

Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–98. https://doi.org/10.1056/NEJMoa2206286.

Article  PubMed  Google Scholar 

Spertus JA, Birmingham MC, Nassif M, et al. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med. 2022;28(4):809–13. https://doi.org/10.1038/s41591-022-01703-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61. https://doi.org/10.1056/NEJMoa2107038.

Article  CAS  PubMed  Google Scholar 

Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27(11):1954–60. https://doi.org/10.1038/s41591-021-01536-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nassif ME, Qintar M, Windsor SL, et al. Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial. Circulation. 2021;143(17):1673–86. https://doi.org/10.1161/circulationaha.120.052503.

Article  CAS  PubMed  Google Scholar 

Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–28. https://doi.org/10.1056/NEJMoa2030183.

Article  CAS  PubMed  Google Scholar 

Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129–39. https://doi.org/10.1056/NEJMoa2030186.

Article  CAS  PubMed  Google Scholar 

Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021;77(3):243–55. https://doi.org/10.1016/j.jacc.2020.11.008.

Article  CAS  PubMed  Google Scholar 

Tanaka A, Hisauchi I, Taguchi I, et al. Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE). ESC Heart Failure. 2020;7(4):1585–94. https://doi.org/10.1002/ehf2.12707.

Article  PubMed  PubMed Central